A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treatment Containing an Anti-CTLA-4 Monoclonal Antibody

Trial Profile

A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treatment Containing an Anti-CTLA-4 Monoclonal Antibody

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Malignant melanoma; Uveal melanoma
  • Focus Adverse reactions
  • Acronyms CheckMate 172
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Jun 2017 Results (n=734; Data cut off November 2016) of first efficacy analysis and updated safety data, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 26 Oct 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Feb 2018.
    • 11 Oct 2016 Results of this and one other study assessing cost analysis and pharmacokinetics of Pembrolizumab and Nivolumab presented at the 41st European Society for Medical Oncology Congress (2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top